Patenting the human genome

May 24, 2013 by Adrienne Wright, Lehigh University

Can human genes be patented? That was the question posed by Alan J. Snyder, vice president and associate provost for research and graduate studies at Lehigh, and Lee Kaplan, scientific director of cellular and molecular genetics at Health Network Laboratories, at a panel discussion on campus this spring.

Snyder and Kaplan examined Association for v. Myriad Genetics Inc., an intellectual property case now before the Supreme Court that could have far-reaching implications for the scientific community as well as for ordinary men and women.

At the center of the case are genes BRCA1 and BRCA2, which made headlines recently when actress Angelina Jolie announced that she had tested positive for mutations of the gene and opted for a preventive to reduce her risk of .

After the genes were sequenced at the University of Utah, patents to them were licensed to Myriad Genetics through a tech transfer. Myriad has excluded outside companies and universities from studying the genes and testing for mutations that could lead to breast and . Instead, the company charges more than $3,000 to administer tests itself.

"Eighty percent of the is patented, but this is one of the few companies that actually enforces their patent to this degree," Kaplan said.

The intricacies of patent law

Previous , said Snyder, have set a precedent for what can be patented under the U.S. Patent Act.

"The definition from Diamond v. Chakrabarty is 'anything under the sun that is made by man.' In that case, the Supreme Court ruled that modifications to DNA are indeed patentable. The only things that are explicitly excluded from being patented are human life forms and so-called 'laws of nature.'"

Indeed, one of the central issues in the Myriad case is the "isolated DNA claim"—whether a gene taken out of the body qualifies as a or as a product of nature.

"Is a gene carved out of a chromosome patentable matter?" Snyder asked.

The Supreme Court is expected to rule on this claim in late June, and Kaplan said the outcome could have a profound impact on scientific innovation and progress.

"There hasn't been much forward movement in the area of breast cancer research because labs aren't able to study this gene," Kaplan said. "BRCA1 was discovered in 1994, so it kind of makes you wonder why there's no drug for this, why nothing has progressed in this field."

Myriad's monopoly on testing, said Kaplan, means that no one is looking over the company's shoulder to validate its work.

"Myriad developed their test to only look at a few points on the gene, so they would send results back and say an individual didn't have the mutation," she said. "Then in 2008 they came under pressure by the scientific community to test more and it turned out there were some gene rearrangements their tests weren't capturing."

A swath of people tested over a 10-year period, he said, may have been given false results.

"You now have these patients who have cancer and who could have had a mastectomy or hysterectomy during those 10 years if they had received accurate results," Kaplan said.

In the end, the ruling will come down to the Court's interpretation of what can be patented.

"The question isn't whether the genes in your body are patentable," Snyder said. "It's whether taking them out of your body and isolating them makes them substantially different."

Explore further: Jolie's mastectomy spotlights legal battle over genes

Related Stories

Jolie's mastectomy spotlights legal battle over genes

May 16, 2013
Movie star Angelina Jolie tested positive for a "faulty gene" at the center of a high-profile legal battle in the United States that challenges whether human genes can belong to a corporation.

Court: Can human genes be patented? (Update)

April 15, 2013
The Supreme Court grapples Monday with the question of whether human genes can be patented, and the ultimate answer could reshape U.S. medical research, the fight against diseases like breast and ovarian cancer and the multi-billion ...

US top court to hear case on gene patents

April 13, 2013
The US Supreme Court will hear arguments Monday on whether to allow private entities to patent genes they have isolated and identified, a decision that could have far-reaching implications for genetic research.

US court to decide if human genes can be patented

November 30, 2012
The Supreme Court announced Friday it will decide whether companies can patent human genes, a decision that could reshape medical research in the United States and the fight against diseases like breast and ovarian cancer.

Recommended for you

Peers' genes may help friends stay in school, new study finds

January 18, 2018
While there's scientific evidence to suggest that your genes have something to do with how far you'll go in school, new research by a team from Stanford and elsewhere says the DNA of your classmates also plays a role.

Two new breast cancer genes emerge from Lynch syndrome gene study

January 18, 2018
Researchers at Columbia University Irving Medical Center and NewYork-Presbyterian have identified two new breast cancer genes. Having one of the genes—MSH6 and PMS2—approximately doubles a woman's risk of developing breast ...

Can mice really mirror humans when it comes to cancer?

January 18, 2018
A new Michigan State University study is helping to answer a pressing question among scientists of just how close mice are to people when it comes to researching cancer.

A centuries-old math equation used to solve a modern-day genetics challenge

January 18, 2018
Researchers developed a new mathematical tool to validate and improve methods used by medical professionals to interpret results from clinical genetic tests. The work was published this month in Genetics in Medicine.

Epigenetics study helps focus search for autism risk factors

January 16, 2018
Scientists have long tried to pin down the causes of autism spectrum disorder. Recent studies have expanded the search for genetic links from identifying genes toward epigenetics, the study of factors that control gene expression ...

Group recreates DNA of man who died in 1827 despite having no body to work with

January 16, 2018
An international team of researchers led by a group with deCODE Genetics, a biopharmaceutical company in Iceland, has partly recreated the DNA of a man who died in 1827, despite having no body to take tissue samples from. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.